Detection of CSF 14-3-3 protein in Guillain-Barré syndrome

A. Bersano, M. Fiorini, S. Allaria, G. Zanusso, E. Fasoli, M. Gelati, H. Monaco, G. Squintani, S. Monaco, E. Nobile-Orazio

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OBJECTIVE: To search for biologic markers in the Guillain-Barré syndrome (GBS), we studied CSF samples from patients with GBS and neuropathy of various etiologies for the presence of 14-3-3 protein. METHODS: CSF samples from patients with GBS, chronic neuropathies, motor neuron disease (MND), definite sporadic Creutzfeldt-Jakob disease (sCJD), and normal control subjects were analyzed by standard immunoblot assay, using a polyclonal anti-14-3-3 antibody. CSF samples were also tested with antibodies recognizing specific isoforms of 14-3-3 proteins, either after one-dimensional or two-dimensional electrophoretic separation. RESULTS: A positive 14-3-3 assay was observed in 29 of 38 patients with GBS and in 4 patients with MND and other neuropathies, including 2 subjects with vasculitic neuropathy (VN). In GBS, 14-3-3 protein was detected as early as 12 to 48 hours after disease onset and showed an isoform pattern different from that encountered in patients with noninflammatory neuropathies, VN, MND, and sCJD. Immunohistochemical studies performed in archival fatal GBS cases disclosed marked 14-3-3 expression by mononuclear inflammatory infiltrates and Schwann cells. CONCLUSION: CSF 14-3-3 assay may represent a useful biologic marker in patients with Guillain-Barré syndrome.

Original languageEnglish
Pages (from-to)2211-2216
Number of pages6
JournalNeurology
Volume67
Issue number12
DOIs
Publication statusPublished - Dec 2006

Fingerprint

14-3-3 Proteins
Motor Neuron Disease
Protein Isoforms
Biomarkers
Antibodies
Schwann Cells

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Detection of CSF 14-3-3 protein in Guillain-Barré syndrome. / Bersano, A.; Fiorini, M.; Allaria, S.; Zanusso, G.; Fasoli, E.; Gelati, M.; Monaco, H.; Squintani, G.; Monaco, S.; Nobile-Orazio, E.

In: Neurology, Vol. 67, No. 12, 12.2006, p. 2211-2216.

Research output: Contribution to journalArticle

Bersano, A, Fiorini, M, Allaria, S, Zanusso, G, Fasoli, E, Gelati, M, Monaco, H, Squintani, G, Monaco, S & Nobile-Orazio, E 2006, 'Detection of CSF 14-3-3 protein in Guillain-Barré syndrome', Neurology, vol. 67, no. 12, pp. 2211-2216. https://doi.org/10.1212/01.wnl.0000249150.98891.d1
Bersano A, Fiorini M, Allaria S, Zanusso G, Fasoli E, Gelati M et al. Detection of CSF 14-3-3 protein in Guillain-Barré syndrome. Neurology. 2006 Dec;67(12):2211-2216. https://doi.org/10.1212/01.wnl.0000249150.98891.d1
Bersano, A. ; Fiorini, M. ; Allaria, S. ; Zanusso, G. ; Fasoli, E. ; Gelati, M. ; Monaco, H. ; Squintani, G. ; Monaco, S. ; Nobile-Orazio, E. / Detection of CSF 14-3-3 protein in Guillain-Barré syndrome. In: Neurology. 2006 ; Vol. 67, No. 12. pp. 2211-2216.
@article{33d946d245c640f092c8fb6bf61d2893,
title = "Detection of CSF 14-3-3 protein in Guillain-Barr{\'e} syndrome",
abstract = "OBJECTIVE: To search for biologic markers in the Guillain-Barr{\'e} syndrome (GBS), we studied CSF samples from patients with GBS and neuropathy of various etiologies for the presence of 14-3-3 protein. METHODS: CSF samples from patients with GBS, chronic neuropathies, motor neuron disease (MND), definite sporadic Creutzfeldt-Jakob disease (sCJD), and normal control subjects were analyzed by standard immunoblot assay, using a polyclonal anti-14-3-3 antibody. CSF samples were also tested with antibodies recognizing specific isoforms of 14-3-3 proteins, either after one-dimensional or two-dimensional electrophoretic separation. RESULTS: A positive 14-3-3 assay was observed in 29 of 38 patients with GBS and in 4 patients with MND and other neuropathies, including 2 subjects with vasculitic neuropathy (VN). In GBS, 14-3-3 protein was detected as early as 12 to 48 hours after disease onset and showed an isoform pattern different from that encountered in patients with noninflammatory neuropathies, VN, MND, and sCJD. Immunohistochemical studies performed in archival fatal GBS cases disclosed marked 14-3-3 expression by mononuclear inflammatory infiltrates and Schwann cells. CONCLUSION: CSF 14-3-3 assay may represent a useful biologic marker in patients with Guillain-Barr{\'e} syndrome.",
author = "A. Bersano and M. Fiorini and S. Allaria and G. Zanusso and E. Fasoli and M. Gelati and H. Monaco and G. Squintani and S. Monaco and E. Nobile-Orazio",
year = "2006",
month = "12",
doi = "10.1212/01.wnl.0000249150.98891.d1",
language = "English",
volume = "67",
pages = "2211--2216",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Detection of CSF 14-3-3 protein in Guillain-Barré syndrome

AU - Bersano, A.

AU - Fiorini, M.

AU - Allaria, S.

AU - Zanusso, G.

AU - Fasoli, E.

AU - Gelati, M.

AU - Monaco, H.

AU - Squintani, G.

AU - Monaco, S.

AU - Nobile-Orazio, E.

PY - 2006/12

Y1 - 2006/12

N2 - OBJECTIVE: To search for biologic markers in the Guillain-Barré syndrome (GBS), we studied CSF samples from patients with GBS and neuropathy of various etiologies for the presence of 14-3-3 protein. METHODS: CSF samples from patients with GBS, chronic neuropathies, motor neuron disease (MND), definite sporadic Creutzfeldt-Jakob disease (sCJD), and normal control subjects were analyzed by standard immunoblot assay, using a polyclonal anti-14-3-3 antibody. CSF samples were also tested with antibodies recognizing specific isoforms of 14-3-3 proteins, either after one-dimensional or two-dimensional electrophoretic separation. RESULTS: A positive 14-3-3 assay was observed in 29 of 38 patients with GBS and in 4 patients with MND and other neuropathies, including 2 subjects with vasculitic neuropathy (VN). In GBS, 14-3-3 protein was detected as early as 12 to 48 hours after disease onset and showed an isoform pattern different from that encountered in patients with noninflammatory neuropathies, VN, MND, and sCJD. Immunohistochemical studies performed in archival fatal GBS cases disclosed marked 14-3-3 expression by mononuclear inflammatory infiltrates and Schwann cells. CONCLUSION: CSF 14-3-3 assay may represent a useful biologic marker in patients with Guillain-Barré syndrome.

AB - OBJECTIVE: To search for biologic markers in the Guillain-Barré syndrome (GBS), we studied CSF samples from patients with GBS and neuropathy of various etiologies for the presence of 14-3-3 protein. METHODS: CSF samples from patients with GBS, chronic neuropathies, motor neuron disease (MND), definite sporadic Creutzfeldt-Jakob disease (sCJD), and normal control subjects were analyzed by standard immunoblot assay, using a polyclonal anti-14-3-3 antibody. CSF samples were also tested with antibodies recognizing specific isoforms of 14-3-3 proteins, either after one-dimensional or two-dimensional electrophoretic separation. RESULTS: A positive 14-3-3 assay was observed in 29 of 38 patients with GBS and in 4 patients with MND and other neuropathies, including 2 subjects with vasculitic neuropathy (VN). In GBS, 14-3-3 protein was detected as early as 12 to 48 hours after disease onset and showed an isoform pattern different from that encountered in patients with noninflammatory neuropathies, VN, MND, and sCJD. Immunohistochemical studies performed in archival fatal GBS cases disclosed marked 14-3-3 expression by mononuclear inflammatory infiltrates and Schwann cells. CONCLUSION: CSF 14-3-3 assay may represent a useful biologic marker in patients with Guillain-Barré syndrome.

UR - http://www.scopus.com/inward/record.url?scp=33845915920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845915920&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000249150.98891.d1

DO - 10.1212/01.wnl.0000249150.98891.d1

M3 - Article

C2 - 17190946

AN - SCOPUS:33845915920

VL - 67

SP - 2211

EP - 2216

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -